MRNA (MRNA)
MRNA is rated NEUTRAL due to a lack of valuation data and an unsuitable floor confidence, despite relatively low implied volatility.
- No valuation data is available (price-to-earnings, price-to-book, or price-to-sales) to assess whether the stock is overvalued or undervalued.
- The floor analysis finds a low-confidence, unsuitable verdict, with no valid or applicable valuation floors detected for the current price of $50.42.
- Implied volatility is low (IV rank of 20.4% over 221 days) and carries no red alerts, but this alone does not tip the balance given the missing fundamental support.
BUY-ZONE DECISION rule signal
Sign in
RULES & ALERTS FIRING
Sign in
VALUATION
Floor Engine
YOUR WATCHLIST CONTEXT
○ anonymous· Your personal floor / golden price overlay on the live price
· Per-ticker rule alerts when this stock crosses your thresholds
· Position P&L overlay — what this ticker means inside your full portfolio
IMPLIED VOLATILITY
Earnings Reactions
| Date | Time | EPS | Surprise | Gap% | Day% | Week% |
|---|---|---|---|---|---|---|
| 2026-04-30 | AMC | -1.18 | +70.2% | +1.51% | -1.24% | +18.31% |
| 2026-02-13 | BMO | -2.11 | +18.9% | +4.34% | +5.29% | +25.38% |
| 2025-11-06 | BMO | -0.51 | +76.4% | +7.13% | +3.27% | +5.94% |
| 2025-08-01 | BMO | -2.13 | +28.3% | -6.73% | -6.61% | -11.64% |
| 2025-05-01 | BMO | -2.52 | +18.9% | -3.01% | -5.29% | -14.58% |
| 2025-02-14 | BMO | -2.91 | -6.7% | -4.35% | +3.35% | +6.20% |
| 2024-11-07 | BMO | 0.03 | +101.5% | +9.25% | -2.95% | -23.24% |
| 2024-08-01 | BMO | -3.33 | +1.0% | -16.47% | -21.01% | -29.27% |
Is MRNA (MRNA) overvalued right now?
Whether MRNA (MRNA) is overvalued depends on the lens you use: trailing P/E vs its own history, CAPE vs the broader market, earnings yield vs Treasury yields. We surface all three so you don't have to pick one in isolation.
MRNA (MRNA) — what's the SELL PUT risk profile?
Selling cash-secured puts on MRNA (MRNA) is a common income strategy, but the right strike depends on your floor price (the level you'd happily own at) and the option chain's buffer/APY tradeoff. The full ladder view (deferred to a future release) ranks candidates by buffer percentage first, then APY — see the option ladder methodology for why buffer matters more than yield in this strategy.
MRNA (MRNA) — which option strategy fits your view?
If you're bullish long-term but cautious near-term on MRNA (MRNA), SELL PUT into your floor zone collects premium while waiting for a better entry. If you already own it and are neutral-to-mildly-bullish, COVERED CALL caps upside but harvests time decay. The wrong strategy on the right ticker still loses money — match the trade to your view, not the other way around.
MRNA (MRNA) — is now a good entry?
Entry timing on MRNA (MRNA) is a function of your floor price (hard buy zone) and golden price (back-the-truck-up zone). Both are personal — set them in your watchlist and we'll alert you when the market hits either level.
FAQ
Why does MRNA show different P/E numbers on different sites?
Different data providers use different earnings windows (TTM vs forward, GAAP vs adjusted) and update at different cadences. We surface trailing P/E with a 5-year percentile rank to give context — a P/E of 30 is hot for one stock and cold for another.
Does this page show MRNA's implied volatility?
Not on this v0 page — the dedicated volatility tool covers IV with multi-source voting (IBKR + Polygon + yfinance). For pure IV lookup, use /tools/volatility. This page is for decision-stage queries that pull together valuation + portfolio context.
How is this different from Yahoo Finance or 雪球's MRNA page?
Those sites are great for raw data discovery — last price, news, headline P/E. This page is built for the second look: you've already seen a single-dimension signal somewhere else, now you need multi-dimensional decision context (your floor, the valuation percentile, your portfolio overlay) in one view, not five tabs.